Advertisement

Announcement

        With the appropriate Editorial leadership, a journal has the capability to truly influence the direction of research and drive the advancement of a field. This has certainly been the case for Gynecologic Oncology and Gynecologic Oncology Reports, which have thrived under the esteemed leadership of Dr. Beth Y. Karlan and Deputy Editors: Drs. Robert E. Bristow, David E. Cohn, Barbara A. Goff, Laurel W. Rice, Stephen C. Rubin, and Anil K. Sood. However, after 15 years of distinguished service to the Journals, SGO, and the community, Dr. Karlan is proud to now hand over the reins to a new editorial team.
        Starting in January 2022, Dr. David E. Cohn will take over as Editor-in-Chief of Gynecologic Oncology and Dr. Susan C. Modesitt will take over as Editor-in-Chief of Gynecologic Oncology Reports.
        Reflection on Dr. Karlan's Leadership
        We are indebted to Dr. Karlan for transforming Gynecologic Oncology into the premier, international journal for the study of women's cancer and, with the help of her Deputy Editor team, for establishing a companion title in 2011 named Gynecologic Oncology Reports. During her tenure, not only were authors and reviewers held to the highest of standards, but these journals continually embraced new and exciting strategies. In Gynecologic Oncology, Dr. Karlan and the Deputy Editors invited leading experts to review timely topics and infused new article types that aim to provide historical perspectives, reflect on the current State of the Science, share intriguing clinical cases and tumor board presentations, and explore the translational potential of molecular and cellular mechanisms of action (e.g., molecularly targeted drug). Gynecologic Oncology Reports has evolved as well and, in addition to case reports, now publishes surgical films, narrative reviews, and survey articles. It also has a dedicated Global Gynecologic Oncology section to advance research and clinical care in resource constrained environments.
        “Beth Y. Karlan, MD began her tenure as third Editor-in-Chief of Gynecologic Oncology in 2008. Under her leadership, the impact of Gynecologic Oncology on the medical and scientific community has grown significantly in breadth and depth. The number of published manuscripts increased two-fold; with 574 articles published in 2006 and 1365 articles published in 2020. The most compelling testament to Dr. Karlan's legacy is the increase in Gynecologic Oncology's Impact Factor (IF) from 2.319 in 2006 to 5.48 in 2020, placing the journal in the top 10% of all obstetrics/gynecology journals and in the top third of all oncology journals. During Dr. Karlan's tenure, Gynecologic Oncology Reports transitioned to an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, and case series in the field of gynecologic oncology.
        As an expert and ambassador of oncology, Dr. Karlan was appointed by the Obama White House to serve on the National Cancer Advisory Board in 2012 and elected to membership in the National Academy of Medicine in 2015. Dr. Karlan is a Fellow of the American Society of Clinical Oncology and was recognized with the OncLive Giants of Cancer award in 2019. She has mentored countless members of the gynecologic oncology community and, through her dedication to Gynecologic Oncology and Gynecologic Oncology Reports has led the advancement of science and recognition of the field of gynecologic oncology in the U.S. and abroad.”
        Pierre Désy, MPH, CAE
        Chief Executive Officer, SGO
        Dr. Karlan's service to both journals and her impact on her colleagues will be felt for years to come. Deputy Editors Barbara Goff and Laurel Rice write:
        “It was truly an honor to work alongside Dr. Karlan. She is a visionary who kept evolving our journal and making sure we were publishing the most cutting-edge science. She developed the partner journal Gynecologic Oncology Reports, invited film submissions, podcasts, and tapped into social media to reach a broader audience. Every year we would add more features and she made sure that our Editorial Board was diverse so that we could be a true international Journal. She was the driving force in the rise of the impact factor. She had high standards for quality, integrity, and the peer review process. But most importantly, Beth was so much fun to work with and her joy of science was infectious.”
        Barbara A. Goff, MD, Deputy Editor
        “Under Dr. Karlan's leadership, our journal has flourished and the increase in impact factor alone supports this declaration. The increased engagement with the entire field, nationally, as well as internationally, is palpable. This has advanced the position and impact of Gynecologic Oncology as a leading academic medical journal and importantly has influenced direct clinical care of our patients. Secondarily, working under her tutelage has been a privilege, allowing me to learn and grow professionally. Her legacy is remarkable and rock solid. I am taking this moment to ‘toast’ her and express my sincere gratitude!”
        Laurel W. Rice, MD, Deputy Editor
        Introducing the Next Editor-in-Chief of Gynecologic Oncology
        David E. Cohn, MD, MBA, FACHE is the Chief Medical Officer of the James Cancer Hospital and Solove Research Institute at Ohio State, a position he has held since 2018. He is a Professor in the Division of Gynecologic Oncology at the Ohio State University College of Medicine, where he has been on faculty since 2001. He holds the Stuart M. Sloan and Larry J. Copeland Chair in Gynecologic Oncology.
        Dr. Cohn was an undergraduate at the University of Michigan, and earned his medical degree at Georgetown University School of Medicine in Washington, D.C. He completed his residency in obstetrics and gynecology at the University of Washington in Seattle and a fellowship at Washington University in St. Louis. He received his MBA from the Fisher College of Business at The Ohio State University and is a fellow of the American College of Healthcare Executives.
        He is on the board of directors of the Society of Gynecologic Oncology, where he currently serves as the Immediate Past President following his term as President from 2020 to 2021. He has published over 275 manuscripts and 20 book chapters. He holds two patents, one for the early detection of ovarian cancer and the other for a novel vaccination strategy for treatment of this disease. He has served as a Deputy Editor of Gynecologic Oncology since 2011.
        Dr. Cohn maintains a practice that includes both a medical and surgical treatment of gynecologic cancers. He has been widely recognized by his peers for excellence in clinical practice, and by those that he educates for his excellence in teaching. His research interests include the investigation of the genetics of endometrial cancer, signaling biology of ovarian cancer, and value-base cancer care delivery.
        Introducing the Next Editor-in-Chief of Gynecologic Oncology Reports
        Dr. Susan C. Modesitt is the Director of the Gynecologic Oncology Division and the Director of the High-Risk Breast/Ovarian Cancer Clinic at the University of Virginia. She is also the Richard and Louise Crockett endowed Professor in Obstetrics and Gynecology. She completed her undergraduate degree at Emory University, medical school at the University of Virginia, her OB/GYN residency at the University of North Carolina and her Gynecologic Oncology fellowship at the M.D. Anderson Cancer Center. She was on faculty at the University of Kentucky until she was recruited back to join the faculty at UVA and she became the Division Director in 2007.
        Dr. Modesitt is a fellow of the American College of Obstetricians and Gynecologists and the American College of Surgeons and has served in multiple leadership roles and committees for the Society of Gynecologic Oncology, the American College of Obstetricians and Gynecologists, the NRG Oncology Group, and the UVA Cancer center. She has published over 100 articles, 10 book chapters, and has been recognized annually as a Top Doctor for Cancer. Her research focuses on hereditary cancers, obesity related cancers, and clinical trials. Outside of work, Dr. Modesitt loves all UVA athletic events, family cycling trips, swimming, hiking and golf and, barring injury, does the occasional triathlon or road race.